ストックスクリーナーアプリを入手
2.97
7.48%
-0.24
前日終値:
$3.21
開ける：
$3.21
24時間の取引高:
1.31M
Relative Volume:
1.61
時価総額：
$212.49M
収益：
-
当期純損益:
$-104.08M
株価収益率:
-2.111
EPS:
-1.4069
ネットキャッシュフロー:
$-89.91M
1週間 パフォーマンス:
-7.76%
1か月 パフォーマンス:
+20.73%
6か月 パフォーマンス:
+42.11%
1年 パフォーマンス:
+65.00%
1日の値動き範囲:
$2.77
$3.22
1週間の範囲:
$2.77
$3.72
52週間の値動き範囲:
$1.70
$3.72
Nkarta Inc Stock (NKTX) Company Profile
名前
Nkarta Inc
セクター
電話
(925) 407-1049
住所
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.97 | 212.49M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-08-14 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-07-28 | 開始されました | Needham | Buy |
| 2022-07-18 | 開始されました | SVB Leerink | Outperform |
| 2022-03-11 | 開始されました | Raymond James | Outperform |
| 2022-03-08 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-06 | 開始されました | William Blair | Outperform |
| 2021-11-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-07-16 | 開始されました | Oppenheimer | Outperform |
| 2020-08-04 | 開始されました | Cowen | Outperform |
| 2020-08-04 | 開始されました | Evercore ISI | Outperform |
| 2020-08-04 | 開始されました | Mizuho | Buy |
| 2020-08-04 | 開始されました | Stifel | Buy |
すべてを表示
Nkarta Inc (NKTX) 最新ニュース
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Price to earnings forward of Nkarta, Inc. – NASDAQ:NKTX - TradingView
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy - Stock Titan
Nkarta Inc (NKTX) Institutional Confidence - TradingKey
Nkarta to present CAR-NK cell therapy updates a... - Pluang
TD Cowen initiates Nkarta stock with buy rating on NK cell therapy - Investing.com
TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating - Moomoo
TD Cowen Initiates Nkarta at Buy - Moomoo
Nkarta (NKTX) CEO reports 1,776-share tax-related sale, holds 390,247 shares - Stock Titan
Nkarta (NKTX) Stock Price, News & Analysis - MarketBeat
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NKTX Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical ProgressEarnings Quality Score - newsline.com
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SharesUpward Estimate Revision - dars.gov.et
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss and Promising Pipeline Updates Spark 12% Rally - newsline.com
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay - TipRanks
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay - Stock Titan
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital - Stock Titan
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027 - Stock Titan
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant - Stock Titan
Nkarta (NKTX) director receives stock options on 37,000 common shares - Stock Titan
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds - Stock Titan
Nkarta director granted options on 37,000 shares | NKTX Insider Trading - Stock Titan
Nkarta (NKTX) director awarded stock options for 37,000 shares at $2.46 - Stock Titan
Nkarta (NKTX) director Angela Thedinga awarded 37,000 stock options - Stock Titan
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineFree Cash Flow Trends - newsline.com
Nkarta Inc. (NKTX) Edges Lower: Assessing Support and Resistance in a Volatile Biotech MarketDefined Outcome ETF - newsline.com
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans - Moomoo
Nkarta Inc. (NKTX) Edges Higher on Above-Average Volume, Nears Key ResistanceDealer Positioning - newsline.com
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressTech Earnings Analysis - The Legal Advocate
NKTXNkarta Inc Short Interest - Finviz
NKTX Q1 2026 Earnings: Narrower-than-expected loss lifts sharesEarnings Quality Analysis - newsline.com
Nkarta Inc. (NKTX) Rallies 3.45% as Buyers Defend Key Support LevelSign of Strength - thelegaladvocate.com
Nkarta’s NK Cell Therapy Push Moves Into Outpatient Care - Finimize
Nkarta Inc. (NKTX) Advances 4.25% as Biotech Sector Momentum BuildsMESA MA - thelegaladvocate.com
Nkarta Inc (NKTX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):